BTIG Maintains Buy on Organogenesis Hldgs, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman has reaffirmed a Buy rating on Organogenesis Holdings (NASDAQ:ORGO) and increased the price target from $4 to $6.
December 27, 2023 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Ryan Zimmerman maintains a Buy rating on Organogenesis Holdings and raises the price target from $4 to $6.
The increase in price target by BTIG reflects a positive outlook on Organogenesis Holdings, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100